Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Systematic Review,HSROC Analysis,and Confounding Factors
Restricted accessResearch articleFirst published online November 19, 2016
Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Systematic Review,HSROC Analysis,and Confounding Factors
Background: Differential diagnosis in dementia is at present one of the main challenges both in clinical practice and research. Cerebrospinal fluid (CSF) biomarkers are included in the current diagnostic criteria of Alzheimer’s disease (AD) but their clinical utility is still unclear.
Objective: We performed a systematic review of studies analyzing the diagnostic performance of CSF Aβ42, total tau (t-tau), and phosphorylated tau (p-tau) in the discrimination between AD and frontotemporal lobar degeneration (FTLD) dementias.
Methods: The following electronic databases were consulted until May 2016: Medline and PreMedline, EMBASE, PsycInfo, CINAHL, Cochrane Library, and CRD. For the first-time in the field, a Hierarchical Summary Receiver Operating Characteristic (HRSOC) model was applied, which avoids methodological problems of meta-analyses based on summary points of sensitivity and specificity values. We also investigated relevant confounders of CSF biomarkers’ diagnostic performance such as age, disease duration, and global cognitive impairment.
Results: The p-tau/Aβ42 ratio showed the best diagnostic performance. No statistically significant effects of the confounders were observed. Nonetheless, the p-tau/Aβ42 ratio may be especially indicated for younger patients. P-tau may be preferable for less cognitively impaired patients (high MMSE scores) and the t-tau/Aβ42 ratio for more cognitively impaired patients (low MMSE scores).
Conclusion: The p-tau/Aβ42 ratio has potential for being implemented in the clinical routine for the differential diagnosis between AD and FTLD. It is of utmost importance that future studies report information on confounders such as age, disease duration, and cognitive impairment, which should also stimulate understanding of the role of these factors in disease mechanisms and pathophysiology.
BraakH, ZetterbergH, Del TrediciK, BlennowK (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol126, 631–641.
5.
OnyikeCU, Diehl-SchmidJ (2013) The epidemiology of frontotemporal dementia. Int Rev Psychiatry25, 130–137.
6.
SeelaarH, RohrerJD, PijnenburgYA, FoxNC, van SwietenJC (2011) Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review. J Neurol Neurosurg Psychiatry82, 476–486.
7.
JosephsKA, HodgesJR, SnowdenJS, MackenzieIR, NeumannM, MannDM, DicksonDW (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol122, 137–153.
GustafsonL (1987) Frontal lobe degeneration of non-Alzheimer type. II. Clinical picture and differential diagnosis. Arch Gerontol Geriatr6, 209–223.
10.
No authors listed (1994) Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry57, 416–418.
11.
McKhannGM, AlbertMS, GrossmanM, MillerB, DicksonD, TrojanowskiJQ (2001) Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol58, 1803–1809.
GrahamA, DaviesR, XuerebJ, HallidayG, KrilJ, CreaseyH, GrahamK, HodgesJ (2005) Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain128, 597–605.
17.
KerteszA, McMonagleP, BlairM, DavidsonW, MunozDG (2005) The evolution and pathology of frontotemporal dementia. Brain128, 1996–2005.
18.
LiscicRM, StorandtM, CairnsNJ, MorrisJC (2007) Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. Arch Neurol64, 535–540.
19.
StopfordCL, SnowdenJS, ThompsonJC, NearyD (2008) Variability in cognitive presentation of Alzheimer’s disease. Cortex44, 185–195.
20.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
21.
MitchellAJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: A meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry80, 966–975.
22.
BloudekLM, SpackmanDE, BlankenburgM, SullivanSD (2011) Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis26, 627–645.
23.
HampelH, BürgerK, TeipelSJ, BokdeALW, ZetterbergH, BlennowK (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement4, 38–48.
24.
Van HartenAC, KesterMI, VisserP-J, BlankensteinMA, PijnenburgYA, van der FlierWM, ScheltensP (2011) Tau and p-tau as CSF biomarkers in dementia: A meta-analysis. Clin Chem Lab Med49, 353–366.
25.
TangW, HuangQ, WangY, WangZ-Y, YaoY-Y (2014) Assessment of CSF Aβ42 as an aid to discriminating Alzheimer’s disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies. J Neurol Sci345, 26–36.
26.
TangW, HuangQ, YaoY-Y, WangY, WuY-L, WangZ-Y (2014) Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J Neural Transm121, 1541–1553.
27.
DahabrehIJ, TrikalinosTA, LauJ, SchmidC (2012) An empirical assessment of bivariate methods for meta-analysis of test accuracy [Internet]. Agency for Healthcare Research and Quality (US), Rockville, MD, 2012 Nov. Report No.: 12(13)-EHC136-EF.
28.
HarbordRM, WhitingP, SterneJA, EggerM, DeeksJJ, ShangA, BachmannLM (2008) An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol61, 1095–1103.
29.
RutterCM, GatsonisCA (2001) A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med20, 2865–2884.
30.
FerreiraD, Perestelo-PérezL, WestmanE, WahlundL-O, SarríaA, Serrano-AguilarP (2014) Meta-review of CSF core biomarkers in Alzheimer’s disease: The state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci6, 1–24.
31.
FerreiraD, Rivero-SantanaA, Perestelo-PérezL, WestmanE, WahlundL-O, SarríaA, Serrano-AguilarP (2014) Improving CSF biomarkers’ performance for predicting progression from mild cognitive impairment to Alzheimer’s disease by considering different confounding factors: A meta-analysis. Front Aging Neurosci6, 287.
32.
Valcárcel-NazcoC, Perestelo-PérezL, MolinuevoJL, MarJ, CastillaI, Serrano-AguilarP (2014) Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer’s disease. J Alzheimers Dis42, 777–788.
33.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanE (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
34.
WhitingPF, RutjesAWS, WestwoodME, MallettS, DeeksJJ, ReitsmaJB, LeeflangMMG, SterneJAC, BossuytPMM (2011) QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med155, 529–536.
35.
LiberatiA, AltmanDG, TetzlaffJ, MulrowC, IoannidisJPA, ClarkeM, DevereauxPJ, KleijnenJ, MoherD (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med151, 65–94.
36.
MoherD, LiberatiA, TetzlaffJ, AltmanDG (2010) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg8, 336–341.
37.
MacaskillP (2004) Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. J Clin Epidemiol57, 925–932.
38.
HarbordR, WhitingP (2009) Metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J9, 211–229.
39.
(1998) Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer’s Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging19, 109–116. Erratum in: Neurobiol Aging 19, 285, 1998.
BaldeirasI, SantanaI, LeitãoMJ, RibeiroMH, PascoalR, DuroD, LemosR, SantiagoB, AlmeidaMR, OliveiraCR (2015) Cerebrospinal fluid Aβ40 is similarly reduced in patients with frontotemporal lobar degeneration and Alzheimer’s disease. J Neurol Sci358, 308–316.
42.
BianH, Van SwietenJC, LeightS, MassimoL, WoodE, FormanM, MooreP, de KoningI, ClarkCM, RossoS, TrojanowskiJ, LeeVM-Y, GrossmanM (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology70, 1827–1835.
43.
BiblM, GallusM, WelgeV, EsselmannH, WolfS, RütherE, WiltfangJ (2012) Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia. J Neural Transm119, 805–813.
44.
BlaskoI, LedererW, OberbauerH, WalchT, KemmlerG, HinterhuberH, MarksteinerJ, HumpelC (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cogn Disord21, 9–15.
45.
BlennowK, WallinA, AgrenH, SpengerC, SiegfriedJ, VanmechelenE (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?Mol Chem Neuropathol26, 231–245.
BuergerK, ZinkowskiR, TeipelSJ, TapiolaT, AraiH, BlennowK, AndreasenN, Hofmann-KieferK, DeBernardisJ, KerkmanD, McCullochC, KohnkenR, PadbergF, PirttiläT, SchapiroMB, RapoportSI, MöllerH-J, DaviesP, HampelH (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol59, 1267–1272.
48.
ClarkCM, XieS, ChittamsJ, EwbankD, PeskindE, GalaskoD, MorrisJC, McKeelDW, FarlowM, WeitlaufSL, QuinnJ, KayeJ, KnopmanD, AraiH, DoodyRS, DeCarliC, LeightS, LeeVM-Y, TrojanowskiJQ (2003) Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses?Arch Neurol60, 1696–1702.
49.
De JongD, JansenRWMM, PijnenburgYA, van GeelWJ, BormGF, KremerHPH, VerbeekMM (2007) CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry78, 936–938.
50.
De RinoF, Martinelli-BoneschiF, CasoF, ZuffiM, ZabeoM, PasseriniG, ComiG, MagnaniG, FranceschiM (2012) CSF metabolites in the differential diagnosis of Alzheimer’s disease from frontal variant of frontotemporal dementia. Neurol Sci33, 973–977.
51.
De SouzaLC, LamariF, BelliardS, JardelC, HouillierC, De PazR, DuboisB, SarazinM (2011) Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. J Neurol Neurosurg Psychiatry82, 240–246.
52.
GabelleA, DumurgierJ, VercruysseO, PaquetC, BomboisS, LaplancheJ-L, Peoc’hK, SchraenS, BuéeL, PasquierF, HugonJ, TouchonJ, LehmannS (2013) Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: The PLM Study. J Alzheimers Dis34, 297–305.
53.
GrossmanM, FarmerJ, LeightS, WorkM, MooreP, Van DeerlinV, PraticoD, ClarkCM, CoslettHB, ChatterjeeA, GeeJ, TrojanowskiJQ, LeeVM-Y (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol57, 721–729.
54.
HampelH, BuergerK, ZinkowskiR, TeipelSJ, GoernitzA, AndreasenN, SjoegrenM, DeBernardisJ, KerkmanD, IshiguroK, OhnoH, VanmechelenE, VandersticheleH, McCullochC, MollerHJ, DaviesPBK (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry61, 95–102.
55.
HerbertMK, AertsMB, KuiperijHB, ClaassenJAHR, SpiesPE, EsselinkRAJ, BloemBR, VerbeekMM (2014) Addition of MHPG to Alzheimer’s disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer’s disease but not other dementias. Alzheimers Dement10, 448–455.e2.
56.
IrwinDJ, McMillanCT, ToledoJB, ArnoldSE, ShawLM, WangL-S, Van DeerlinV, LeeVM-Y, TrojanowskiJQ, GrossmanM (2012) Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol69, 1018–1025.
57.
KapakiE, ParaskevasGP, PapageorgiouSG, BonakisA, KalfakisN, ZalonisI, VassilopoulosD (2008) Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord22, 47–53.
58.
KoopmanK, Le BastardN, MartinJ-J, NagelsG, De DeynPP, EngelborghsS (2009) Improved discrimination of autopsy-confirmed Alzheimer’s disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int55, 214–218.
59.
ParaskevasGP, KapakiE, LiappasI, TheotokaI, MamaliI, ZournasC, LykourasL (2005) The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol18, 163–173.
60.
PetzoldA, ChapmanMD, SchraenS, VerweyNA, PasquierF, BomboisS, BrettschneiderJ, FoxNC, von ArnimCAF, TeunissenC, PijnenburgY, RiepeMW, OttoM, TumaniH, ScheltensP, BueeL, RossorMN (2010) An unbiased, staged, multicentre, validation strategy for Alzheimer’s disease CSF tau levels. Exp Neurol223, 432–438.
61.
PijnenburgYAL, SchoonenboomNSM, RossoSM, MulderC, Van KampGJ, Van SwietenJC, ScheltensP (2004) CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration. Neurology62, 1649.
62.
RiemenschneiderM, WagenpfeilS, DiehlJ, LautenschlagerN, ThemlT, HeldmannB, DrzezgaA, JahnT, FörstlH, KurzA (2002) Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology58, 1622–1628.
63.
SchoonenboomNSM, PijnenburgYAL, MulderC, RossoSM, ElkE, Van KampG, van SwietenJ, van ScheltensP (2004) Amyloid beta (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology62, 1580–1584.
64.
SeeburgerJL, HolderDJ, CombrinckM, JoachimC, LaterzaO, TanenM, DallobA, ChappellD, SnyderK, FlynnM, SimonA, ModurV, PotterWZ, WilcockG, SavageMJ, SmithAD (2015) Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer’s disease from other dementias and healthy controls in the OPTIMA cohort. J Alzheimers Dis44, 525–539.
65.
SjögrenM, RosengrenL, MinthonL, DavidssonP, BlennowK, WallinA (2000) Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology54, 1960–1964.
66.
SjögrenM, DavidssonP, TullbergM, MinthonL, WallinA, WikkelsoC, GranérusAK, VandersticheleH, VanmechelenE, BlennowK (2001) Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry70, 624–630.
67.
SkillbäckT, FarahmandBY, RosénC, MattssonN, NäggaK, KilanderL, ReligaD, WimoA, WinbladB, SchottJM, BlennowK, EriksdotterM, ZetterbergH (2015) Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain138, 2716–2731.
68.
StruyfsH, Van BroeckB, TimmersM, FransenE, SleegersK, Van BroeckhovenC, De DeynPP, StrefferJR, MerckenM, EngelborghsS (2015) Diagnostic accuracy of cerebrospinal fluid amyloid-β isoforms for early and differential dementia diagnosis. J Alzheimers Dis45, 813–822.
VerweyNA, KesterMI, van der FlierWM, VeerhuisR, BerkhofH, TwaalfhovenH, BlankensteinMA, ScheltensP, PijnenburgYA (2010) Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis20, 445–452.
71.
HoltzmanDM (2011) CSF biomarkers for Alzheimer’s disease: Current utility and potential future use. Neurobiol Aging32(Suppl 1), S4–S9.
72.
AnoopA, SinghPK, JacobRS, MajiSK (2010) CSF biomarkers for Alzheimer’s disease diagnosis. Int J Alzheimers Dis2010, 606802.
73.
LorenziM, PennecX, FrisoniGB, AyacheN (2015) Disentangling normal aging from Alzheimer’s disease in structural magnetic resonance images. Neurobiol Aging36(Suppl 1), S42–S52.
74.
BouwmanFH, SchoonenboomNSM, VerweyNA, van ElkEJ, KokA, BlankensteinMA, ScheltensP, van der FlierWM (2009) CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol Aging30, 1895–1901.
75.
MattssonN, RosénE, HanssonO, AndreasenN, ParnettiL, JonssonM, HerukkaS-K, van der FlierWM, BlankensteinMA, EwersM, RichK, KaiserE, VerbeekMM, Olde RikkertM, TsolakiM, MulugetaE, AarslandD, VisserPJ, SchröderJ, MarcussonJ, de LeonM, HampelH, ScheltensP, WallinA, Eriksdotter-JönhagenM, MinthonL, WinbladB, BlennowK, ZetterbergH (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology78, 468–476.
76.
LiX, LiT-Q, AndreasenN, WibergMK, WestmanE, WahlundL-O (2014) The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer’s disease. J Intern Med275, 418–427.
77.
LiX, LiT-Q, AndreasenN, WibergMK, WestmanE, WahlundL-O (2013) Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD. Sci Rep3, 1339.
78.
OrellanaC, FerreiraD, MecocciP, VellasB, TsolakiM, KłoszewskaI, SoininenH, LovestoneS, SimmonsA, WahlundL-O, WestmanE (2016) Measuring global brain atrophy with the brain volume / cerebrospinal fluid index: Normative values, cut-offs, and clinical associations. Neurodegener Dis16, 77–86.
79.
HalesCM, HuWT (2013) From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. Int Rev Psychiatry25, 210–220.
80.
HodgesJR, MitchellJ, DawsonK, SpillantiniMG, XuerebJH, McMonagleP, NestorPJ, PattersonK (2010) Semantic dementia: Demography, familial factors and survival in a consecutive series of 100 cases. Brain133, 300–306.
81.
JosephsKA, StrohA, DuggerB, DicksonDW (2009) Evaluation of subcortical pathology and clinical correlations in FTLDU subtypes. Acta Neuropathol118, 349–358.
82.
JosephsKA, PetersenRC, KnopmanDS, BoeveBF, WhitwellJL, DuffyJR, ParisiJE, DicksonDW (2006) Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology66, 41–48.
MioshiE, HsiehS, SavageS, HornbergerM, HodgesJR (2010) Clinical staging and disease progression in frontotemporal dementia. Neurology74, 1591–1597.
92.
FerreiraD, JelicV, CavallinL, OeksengaardAR, SnaedalJ, HøghP, Bo AndersenB, NaikM, EngedalK, WestmanE, WahlundLO (2016) Electroencephalography is a good complement to currently established dementia biomarkers. Dement Geriatr Cogn Disord42, 80–92.
